Literature DB >> 33321791

Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies.

Daniël F Osses1,2, Christian Arsov3, Lars Schimmöller4, Ivo G Schoots2, Geert J L H van Leenders5, Irene Esposito6, Sebastiaan Remmers1, Peter Albers3, Monique J Roobol1.   

Abstract

We aimed to investigate the relation between largest lesion diameter, prostate-specific antigen density (PSA-D), age, and the detection of clinically significant prostate cancer (csPCa) using first-time targeted biopsy (TBx) in men with Prostate Imaging-Reporting and Data System (PI-RADS) 3 index lesions. A total of 292 men (2013-2019) from two referral centers were included. A multivariable logistic regression analysis was performed. The discrimination and clinical utility of the built model was assessed by the area under the receiver operation curve (AUC) and decision curve analysis, respectively. A higher PSA-D and higher age were significantly related to a higher risk of detecting csPCa, while the largest index lesion diameter was not. The discrimination of the model was 0.80 (95% CI 0.73-0.87). When compared to a biopsy-all strategy, decision curve analysis showed a higher net benefit at threshold probabilities of ≥2%. Accepting a missing ≤5% of csPCa diagnoses, a risk-based approach would result in 34% of TBx sessions and 23% of low-risk PCa diagnoses being avoided. In men with PI-RADS 3 index lesions scheduled for first-time TBx, the balance between the number of TBx sessions, the detection of low-risk PCa, and the detection of csPCa does not warrant a biopsy-all strategy. To minimize the risk of missing the diagnosis of csPCa but acknowledging the need of avoiding unnecessary TBx sessions and overdiagnosis, a risk-based approach is advisable.

Entities:  

Keywords:  clinically significant prostate cancer; equivocal PI-RADS lesions; prostate MRI; risk stratification; targeted biopsies

Year:  2020        PMID: 33321791      PMCID: PMC7768373          DOI: 10.3390/jpm10040270

Source DB:  PubMed          Journal:  J Pers Med        ISSN: 2075-4426


  37 in total

1.  Proposed Adjustments to PI-RADS Version 2 Decision Rules: Impact on Prostate Cancer Detection.

Authors:  Andrew B Rosenkrantz; James S Babb; Samir S Taneja; Justin M Ream
Journal:  Radiology       Date:  2016-10-26       Impact factor: 11.105

Review 2.  Score 3 prostate lesions: a gray zone for PI-RADS v2.

Authors:  Michele Scialpi; Eugenio Martorana; Maria Cristina Aisa; Valeria Rondoni; Alfredo D'Andrea; Giampaolo Bianchi
Journal:  Turk J Urol       Date:  2017-08-03

3.  PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2.

Authors:  Jeffrey C Weinreb; Jelle O Barentsz; Peter L Choyke; Francois Cornud; Masoom A Haider; Katarzyna J Macura; Daniel Margolis; Mitchell D Schnall; Faina Shtern; Clare M Tempany; Harriet C Thoeny; Sadna Verma
Journal:  Eur Urol       Date:  2015-10-01       Impact factor: 20.096

4.  Evaluation of MRI for diagnosis of extraprostatic extension in prostate cancer.

Authors:  Satheesh Krishna; Christopher S Lim; Matthew D F McInnes; Trevor A Flood; Wael M Shabana; Robert S Lim; Nicola Schieda
Journal:  J Magn Reson Imaging       Date:  2017-04-07       Impact factor: 4.813

5.  Risk Stratification Among Men With Prostate Imaging Reporting and Data System version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary?

Authors:  Ely R Felker; Steven S Raman; Daniel J Margolis; David S K Lu; Nicholas Shaheen; Shyam Natarajan; Devi Sharma; Jiaoti Huang; Fred Dorey; Leonard S Marks
Journal:  AJR Am J Roentgenol       Date:  2017-08-31       Impact factor: 3.959

6.  Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2--sparse versus dense cancers.

Authors:  Deanna L Langer; Theodorus H van der Kwast; Andrew J Evans; Laibao Sun; Martin J Yaffe; John Trachtenberg; Masoom A Haider
Journal:  Radiology       Date:  2008-12       Impact factor: 11.105

7.  Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.

Authors:  Arnout R Alberts; Monique J Roobol; Jan F M Verbeek; Ivo G Schoots; Peter K Chiu; Daniël F Osses; Jasper D Tijsterman; Harrie P Beerlage; Christophe K Mannaerts; Lars Schimmöller; Peter Albers; Christian Arsov
Journal:  Eur Urol       Date:  2018-08-03       Impact factor: 20.096

8.  Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium.

Authors:  Mieke Van Hemelrijck; Xi Ji; Jozien Helleman; Monique J Roobol; Wim van der Linden; Daan Nieboer; Chris H Bangma; Mark Frydenberg; Antti Rannikko; Lui S Lee; Vincent J Gnanapragasam; Mike W Kattan
Journal:  Eur Urol       Date:  2018-10-29       Impact factor: 20.096

9.  Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate Cancer.

Authors:  Wulphert Venderink; Annemarijke van Luijtelaar; Joyce G R Bomers; Marloes van der Leest; Christina Hulsbergen-van de Kaa; Jelle O Barentsz; J P Michiel Sedelaar; Jurgen J Fütterer
Journal:  Eur Urol       Date:  2017-02-28       Impact factor: 20.096

10.  Clinical evaluation and disease management of PI-RADS 3 lesions. Analysis from a single tertiary high-volume center.

Authors:  Ettore Di Trapani; Gennaro Musi; Matteo Ferro; Giovanni Cordima; Francesco Alessandro Mistretta; Stefano Luzzago; Roberto Bianchi; Gabriele Cozzi; Sarah Alessi; Michele Catellani; Deliu Victor Matei; Barbara Alicja Jereczek-Fossa; Giuseppe Petralia; Ottavio De Cobelli
Journal:  Scand J Urol       Date:  2020-08-10       Impact factor: 1.612

View more
  3 in total

1.  Simplified PI-RADS (S-PI-RADS) for biparametric MRI to detect and manage prostate cancer: What urologists need to know.

Authors:  Michele Scialpi; Pietro Scialpi; Eugenio Martorana; Riccardo Torre; Antonio Improta; Maria Cristina Aisa; Alfredo D'Andrea; Aldo Di Blasi
Journal:  Turk J Urol       Date:  2021-05

2.  Histo-MRI map study protocol: a prospective cohort study mapping MRI to histology for biomarker validation and prediction of prostate cancer.

Authors:  Saurabh Singh; Manju Mathew; Thomy Mertzanidou; Shipra Suman; Joey Clemente; Adam Retter; Marianthi-Vasiliki Papoutsaki; Lorna Smith; Francesco Grussu; Veeru Kasivisvanathan; Alistair Grey; Eoin Dinneen; Greg Shaw; Martyn Carter; Dominic Patel; Caroline M Moore; David Atkinson; Eleftheria Panagiotaki; Aiman Haider; Alex Freeman; Daniel Alexander; Shonit Punwani
Journal:  BMJ Open       Date:  2022-04-08       Impact factor: 2.692

3.  Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate.

Authors:  M Boschheidgen; L Schimmöller; S Doerfler; R Al-Monajjed; J Morawitz; F Ziayee; D Mally; M Quentin; C Arsov; P Albers; G Antoch; T Ullrich
Journal:  Sci Rep       Date:  2022-04-25       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.